IDEXX Laboratories Outlines 2026 Revenue and EPS Guidance
IDEXX Laboratories (IDXX) has provided financial guidance for the year 2026, projecting annual revenue between $4.741 billion and $4.767 billion. The company also expects earnings per share (EPS) to fall within the range of $14.96 to $15.16. Management attributed recent financial performance to strong global execution and the increasing adoption of diagnostic innovations in medical practice. Additionally, the integration or impact of CoVet is expected to contribute approximately $5 million to the company's results.
Tickers: $IDXX
Topics: diagnostics earnings results financial performance global execution
Read the full article at Seeking Alpha
Part of the story IDEXX outlines 2026 revenue of $4.741B-$4.767B and EPS of $14.96-$15.16 as CoVet adds about $5M (2 articles)